Evidence map›Paper›PMID 28222223›Full record

ArticleCA: a cancer journal for clinicians2017

Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Mark K Buyyounouski, Peter L Choyke, Jesse K McKenney, Oliver Sartor, Howard M Sandler, Mahul B Amin, Michael W Kattan, Daniel W Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CA: a cancer journal for clinicians, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mark K BuyyounouskiAssociate Professor of Radiation Oncology, Department of Radiation Oncology, Stanford University, Stanford, CA.
Peter L ChoykeDirector, Molecular Imaging Program, National Cancer Institute, Rockville, MD.
Jesse K McKenneySection Head, Surgical Pathology, Robert J. Tomisch Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Oliver SartorHematology/Oncology Section Chief and Professor of Radiation Oncology, Departments of Medicine and Urology, Tulane Medical School, New Orleans, LA.
Howard M SandlerChair, Department of Radiation Oncology, and Professor of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.
Mahul B AminChair, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN.
Michael W KattanChair, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-3840-4161
Daniel W LinChief of Urologic Oncology, Department of Urology, University of Washington, and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ-confined disease based on prostate-specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostate cancer biomarkers and tools for their ability to prognosticate and guide treatment decision making with the highest level of accuracy and confidence for patients and physicians. CA Cancer J Clin 2017;67:245-253. © 2017 American Cancer Society.

Indexed as

HumansMaleNeoplasm GradingNeoplasm StagingPrognosisProstatic NeoplasmsRadiographyAmerican Joint Committee on Cancer (AJCC)Gleason scoregroup gradeprognosisprostate cancerprostate-specific antigenstaging

Identifiers

PMID28222223
PMCPMC6375094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.